CTMX - CytomX Therapeutics, Inc.
IEX Last Trade
1.075
-0.125 -11.628%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$1.20
-0.13
-10.42%
Fundamental analysis
24%
Profitability
14%
Dept financing
25%
Liquidity
32%
Performance
31%
Performance
5 Days
-1.83%
1 Month
11.42%
3 Months
-8.55%
6 Months
-11.57%
1 Year
-25.69%
2 Year
-30.97%
Key data
Stock price
$1.08
DAY RANGE
$1.10 - $1.20
52 WEEK RANGE
$0.88 - $5.06
52 WEEK CHANGE
-$30.97
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Sean A. McCarthy
Region: US
Website: cytomx.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cytomx.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
CytomX Therapeutics, Inc. develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the. treatment of breast cancer, head and neck squamous cell carcinoma, and diffuse large B-cell lymphoma.
Recent news